Rhythm adds $1.5B as oral MC4R rivals injectable in rare obesity setting

New Phase II data suggest Rhythm’s oral MC4R agonist bivamelagon delivers safety and efficacy comparable to the company’s more advanced injectable therapy for acquired hypothalamic obesity. The results closely follow the injectable readout and support multiple modes of administration, which could help meet the diverse needs of adolescent patients.

Shares of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) rose 37% following Wednesday’s announcement, adding more than $1.5 billion to the biotech’s market cap...